{
    "xml": "<topic id=\"PHP2558\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/granisetron\" basename=\"granisetron\" title=\"GRANISETRON\">\n<title>GRANISETRON</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1296\" namespace=\"/interactions/list-of-drug-interactions/5ht3-receptor-antagonists/granisetron\">Granisetron</xref>\n</p>\n<data name=\"vtmid\">108424001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_495132402\" title=\"5HT&#1079; receptor antagonists\">5HT&#1079; receptor antagonists</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP61324\" outputclass=\"drugAction\" rev=\"1.9\" parent=\"/drugs/granisetron\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Granisetron is a specific 5HT<sub>3</sub>-receptor antagonist which blocks 5HT<sub>3</sub> receptors in the gastro-intestinal tract and in the CNS.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60492\" outputclass=\"indicationsAndDose\" rev=\"1.34\" parent=\"/drugs/granisetron\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Nausea and vomiting induced by cytotoxic chemotherapy for planned duration of 3&#8211;5 days where oral antiemetics cannot be used</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By transdermal application using patches</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Apply 3.1&#8239;mg/24 hours, apply patch to clean, dry, non-irritated, non-hairy skin on upper arm (or abdomen if upper arm cannot be used) 24&#8211;48 hours before treatment, patch may be worn for up to 7 days; remove at least 24 hours after completing chemotherapy.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of postoperative nausea and vomiting</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;mg, to be administered before induction of anaesthesia, dose to be diluted to 5&#8239;mL and given over 30 seconds.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of postoperative nausea and vomiting</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;mg, dose to be diluted to 5&#8239;mL and given over 30 seconds; maximum 3&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of nausea and vomiting induced by cytotoxic chemotherapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;2&#8239;mg, to be taken within 1 hour before start of treatment, then 2&#8239;mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9&#8239;mg in 24 hours.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8211;40&#8239;micrograms/kg (max. per dose 3&#8239;mg), to be given 5 minutes before start of chemotherapy, for intravenous injection, each 1&#8239;mg granisetron diluted to 5&#8239;mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of nausea and vomiting induced by cytotoxic chemotherapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;2&#8239;mg, to be taken within 1 hour before start of treatment, then 2&#8239;mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9&#8239;mg in 24 hours.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8211;40&#8239;micrograms/kg (max. per dose 3&#8239;mg), repeated if necessary, further maintenance doses must not be given less than 10 minutes apart, for intravenous injection, each 1&#8239;mg granisetron diluted to 5&#8239;mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of nausea and vomiting induced by radiotherapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;2&#8239;mg, to be taken within 1 hour before start of treatment, then 2&#8239;mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9&#8239;mg in 24 hours.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8211;40&#8239;micrograms/kg (max. per dose 3&#8239;mg), to be given 5 minutes before start of chemotherapy, for intravenous injection, each 1&#8239;mg granisetron diluted to 5&#8239;mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of nausea and vomiting induced by radiotherapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;2&#8239;mg, to be taken within 1 hour before start of treatment, then 2&#8239;mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9&#8239;mg in 24 hours.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>10&#8211;40&#8239;micrograms/kg (max. per dose 3&#8239;mg), repeated if necessary, further maintenance doses must not be given less than 10 minutes apart, for intravenous injection, each 1&#8239;mg granisetron diluted to 5&#8239;mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62133\" outputclass=\"cautions\" rev=\"1.17\" parent=\"/drugs/granisetron\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Subacute intestinal obstruction</ph>; <ph outputclass=\"caution\">susceptibility to QT-interval prolongation (including electrolyte disturbances)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60385\" outputclass=\"interactions\" rev=\"1.14\" parent=\"/drugs/granisetron\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (5HT<sub>3</sub>-receptor Antagonists).</p>\n<p>Caution with concomitant use of drugs that prolong QT interval.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP59788\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/granisetron\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<title>General side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Constipation</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">insomnia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Extrapyramidal reactions</ph>; <ph outputclass=\"sideEffect\">QT-interval prolongation</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"specificSideEffects\">\n<title>Specific side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With transdermal use</p>\n<p>\n<ph outputclass=\"sideEffect\">application-site reactions</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60271\" outputclass=\"pregnancy\" parent=\"/drugs/granisetron\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62310\" outputclass=\"breastFeeding\" parent=\"/drugs/granisetron\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60910\" outputclass=\"hepaticImpairment\" parent=\"/drugs/granisetron\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use with caution.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62872\" outputclass=\"directionsForAdministration\" rev=\"1.14\" parent=\"/drugs/granisetron\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i>, give intermittently in Glucose 5% or Sodium Chloride 0.9%; dilute up to 3&#8239;mL in 20&#8211;50&#8239;mL infusion fluid; give over 5 minutes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60156\" outputclass=\"patientAndCarerAdvice\" rev=\"1.10\" parent=\"/drugs/granisetron\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">transdermal</ph> use</p>\n<p>Patients should be advised not to expose the site of the patch to sunlight during use and for 10 days after removal.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2558-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/granisetron\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77573\" title=\"Tablet\" namespace=\"/drugs/granisetron/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77577\" title=\"Solution for injection\" namespace=\"/drugs/granisetron/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77581\" title=\"Transdermal patch\" namespace=\"/drugs/granisetron/transdermal-patch\">Transdermal patch</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78221\" namespace=\"/treatment-summaries/nausea-and-labyrinth-disorders\" title=\"Nausea and labyrinth disorders\" count=\"1\" rel=\"backlink\">Nausea and labyrinth disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1296\" namespace=\"/interactions/list-of-drug-interactions/5ht3-receptor-antagonists/granisetron\" title=\"Granisetron\" count=\"1\" rel=\"link\">Granisetron</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77573\" namespace=\"/drugs/granisetron/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77577\" namespace=\"/drugs/granisetron/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77581\" namespace=\"/drugs/granisetron/transdermal-patch\" title=\"Transdermal patch\" count=\"1\" rel=\"link\">Transdermal patch</xref>\n</links>\n</topic>",
    "id": "PHP2558",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/granisetron",
    "basename": "granisetron",
    "title": "GRANISETRON",
    "interactants": [
        {
            "id": "bnf_int_1296",
            "label": "Granisetron"
        }
    ],
    "vtmid": "108424001",
    "drugClassification": [
        "5HT&#1079; receptor antagonists"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Granisetron is a specific 5HT3-receptor antagonist which blocks 5HT3 receptors in the gastro-intestinal tract and in the CNS.",
                "html": "<p>Granisetron is a specific 5HT<sub>3</sub>-receptor antagonist which blocks 5HT<sub>3</sub> receptors in the gastro-intestinal tract and in the CNS.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Nausea and vomiting induced by cytotoxic chemotherapy for planned duration of 3&#8211;5 days where oral antiemetics cannot be used",
                        "html": "Nausea and vomiting induced by cytotoxic chemotherapy for planned duration of 3&#8211;5 days where oral antiemetics cannot be used"
                    }
                ],
                "specificity": {
                    "routes": [
                        "transdermal application using patches"
                    ],
                    "textContent": "By transdermal application using patches",
                    "html": "By transdermal application using patches"
                },
                "adult": [
                    {
                        "textContent": "Apply 3.1 mg/24 hours, apply patch to clean, dry, non-irritated, non-hairy skin on upper arm (or abdomen if upper arm cannot be used) 24&#8211;48 hours before treatment, patch may be worn for up to 7 days; remove at least 24 hours after completing chemotherapy.",
                        "html": "<p>Apply 3.1&#8239;mg/24 hours, apply patch to clean, dry, non-irritated, non-hairy skin on upper arm (or abdomen if upper arm cannot be used) 24&#8211;48 hours before treatment, patch may be worn for up to 7 days; remove at least 24 hours after completing chemotherapy.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of postoperative nausea and vomiting",
                        "html": "Prevention of postoperative nausea and vomiting"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection"
                    ],
                    "textContent": "By intravenous injection",
                    "html": "By intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "1 mg, to be administered before induction of anaesthesia, dose to be diluted to 5 mL and given over 30 seconds.",
                        "html": "<p>1&#8239;mg, to be administered before induction of anaesthesia, dose to be diluted to 5&#8239;mL and given over 30 seconds.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of postoperative nausea and vomiting",
                        "html": "Treatment of postoperative nausea and vomiting"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection"
                    ],
                    "textContent": "By intravenous injection",
                    "html": "By intravenous injection"
                },
                "adult": [
                    {
                        "textContent": "1 mg, dose to be diluted to 5 mL and given over 30 seconds; maximum 3 mg per day.",
                        "html": "<p>1&#8239;mg, dose to be diluted to 5&#8239;mL and given over 30 seconds; maximum 3&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of nausea and vomiting induced by cytotoxic chemotherapy",
                        "html": "Prevention of nausea and vomiting induced by cytotoxic chemotherapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intravenous injection or by intravenous infusion",
                    "html": "By intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;2 mg, to be taken within 1 hour before start of treatment, then 2 mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9 mg in 24 hours.",
                        "html": "<p>1&#8211;2&#8239;mg, to be taken within 1 hour before start of treatment, then 2&#8239;mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9&#8239;mg in 24 hours.</p>"
                    },
                    {
                        "textContent": "10&#8211;40 micrograms/kg (max. per dose 3 mg), to be given 5 minutes before start of chemotherapy, for intravenous injection, each 1 mg granisetron diluted to 5 mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9 mg per day.",
                        "html": "<p>10&#8211;40&#8239;micrograms/kg (max. per dose 3&#8239;mg), to be given 5 minutes before start of chemotherapy, for intravenous injection, each 1&#8239;mg granisetron diluted to 5&#8239;mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of nausea and vomiting induced by cytotoxic chemotherapy",
                        "html": "Treatment of nausea and vomiting induced by cytotoxic chemotherapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intravenous injection or by intravenous infusion",
                    "html": "By intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;2 mg, to be taken within 1 hour before start of treatment, then 2 mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9 mg in 24 hours.",
                        "html": "<p>1&#8211;2&#8239;mg, to be taken within 1 hour before start of treatment, then 2&#8239;mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9&#8239;mg in 24 hours.</p>"
                    },
                    {
                        "textContent": "10&#8211;40 micrograms/kg (max. per dose 3 mg), repeated if necessary, further maintenance doses must not be given less than 10 minutes apart, for intravenous injection, each 1 mg granisetron diluted to 5 mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9 mg per day.",
                        "html": "<p>10&#8211;40&#8239;micrograms/kg (max. per dose 3&#8239;mg), repeated if necessary, further maintenance doses must not be given less than 10 minutes apart, for intravenous injection, each 1&#8239;mg granisetron diluted to 5&#8239;mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of nausea and vomiting induced by radiotherapy",
                        "html": "Prevention of nausea and vomiting induced by radiotherapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intravenous injection or by intravenous infusion",
                    "html": "By intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;2 mg, to be taken within 1 hour before start of treatment, then 2 mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9 mg in 24 hours.",
                        "html": "<p>1&#8211;2&#8239;mg, to be taken within 1 hour before start of treatment, then 2&#8239;mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9&#8239;mg in 24 hours.</p>"
                    },
                    {
                        "textContent": "10&#8211;40 micrograms/kg (max. per dose 3 mg), to be given 5 minutes before start of chemotherapy, for intravenous injection, each 1 mg granisetron diluted to 5 mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9 mg per day.",
                        "html": "<p>10&#8211;40&#8239;micrograms/kg (max. per dose 3&#8239;mg), to be given 5 minutes before start of chemotherapy, for intravenous injection, each 1&#8239;mg granisetron diluted to 5&#8239;mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of nausea and vomiting induced by radiotherapy",
                        "html": "Treatment of nausea and vomiting induced by radiotherapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intravenous injection or by intravenous infusion",
                    "html": "By intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;2 mg, to be taken within 1 hour before start of treatment, then 2 mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9 mg in 24 hours.",
                        "html": "<p>1&#8211;2&#8239;mg, to be taken within 1 hour before start of treatment, then 2&#8239;mg daily in 1&#8211;2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9&#8239;mg in 24 hours.</p>"
                    },
                    {
                        "textContent": "10&#8211;40 micrograms/kg (max. per dose 3 mg), repeated if necessary, further maintenance doses must not be given less than 10 minutes apart, for intravenous injection, each 1 mg granisetron diluted to 5 mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9 mg per day.",
                        "html": "<p>10&#8211;40&#8239;micrograms/kg (max. per dose 3&#8239;mg), repeated if necessary, further maintenance doses must not be given less than 10 minutes apart, for intravenous injection, each 1&#8239;mg granisetron diluted to 5&#8239;mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9&#8239;mg per day.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Subacute intestinal obstruction",
                "html": "Subacute intestinal obstruction"
            },
            {
                "type": "cautions",
                "textContent": "susceptibility to QT-interval prolongation (including electrolyte disturbances)",
                "html": "susceptibility to QT-interval prolongation (including electrolyte disturbances)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (5HT3-receptor Antagonists).\n\nCaution with concomitant use of drugs that prolong QT interval.",
                "html": "<p>Appendix 1 (5HT<sub>3</sub>-receptor Antagonists).</p><p>Caution with concomitant use of drugs that prolong QT interval.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Constipation",
                        "html": "Constipation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "insomnia",
                        "html": "insomnia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Extrapyramidal reactions",
                        "html": "Extrapyramidal reactions",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "QT-interval prolongation",
                        "html": "QT-interval prolongation",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ]
            }
        },
        "specific": {
            "frequencies": {
                "uncommon": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "application-site reactions",
                        "html": "application-site reactions",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "With transdermal use",
                            "html": "With transdermal use",
                            "routes": [
                                "transdermal"
                            ]
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid.",
                "html": "<p>Manufacturer advises avoid.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;no information available.",
                "html": "<p>Avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use with caution.",
                "html": "<p>Manufacturer advises use with caution.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion, give intermittently in Glucose 5% or Sodium Chloride 0.9%; dilute up to 3 mL in 20&#8211;50 mL infusion fluid; give over 5 minutes.",
                "html": "<p>For <i>intravenous infusion</i>, give intermittently in Glucose 5% or Sodium Chloride 0.9%; dilute up to 3&#8239;mL in 20&#8211;50&#8239;mL infusion fluid; give over 5 minutes.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "specificity": {
                    "textContent": "With transdermal use",
                    "html": "With <ph outputclass=\"route\">transdermal</ph> use",
                    "routes": [
                        "transdermal"
                    ]
                },
                "textContent": "Patients should be advised not to expose the site of the patch to sunlight during use and for 10 days after removal.",
                "html": "<p>Patients should be advised not to expose the site of the patch to sunlight during use and for 10 days after removal.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77573",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77577",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77581",
                "label": "Transdermal patch",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78221",
                "label": "Nausea and labyrinth disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1296",
                "label": "Granisetron",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77573",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77577",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77581",
                "label": "Transdermal patch",
                "type": "medicinalForm"
            }
        ]
    }
}